Silver Michelle I, Schiffman Mark, Fetterman Barbara, Poitras Nancy E, Gage Julia C, Wentzensen Nicolas, Lorey Thomas, Kinney Walter K, Castle Philip E
Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.
Regional Laboratory, Kaiser Permanente Northern California, Berkeley, California.
Cancer. 2016 Dec 1;122(23):3682-3686. doi: 10.1002/cncr.30277. Epub 2016 Sep 22.
The objective of cervical screening is to detect and treat precancer to prevent cervical cancer mortality and morbidity while minimizing overtreatment of benign human papillomavirus (HPV) infections and related minor abnormalities. HPV/cytology cotesting at extended 5-year intervals currently is a recommended screening strategy in the United States, but the interval extension is controversial. In the current study, the authors examined the impact of a decade of an alternative, 3-year cotesting, on rates of precancer and cancer at Kaiser Permanente Northern California. The effect on screening efficiency, defined as numbers of cotests/colposcopy visits needed to detect a precancer, also was considered.
Two cohorts were defined. The "open cohort" included all women screened at least once during the study period; > 1 million cotests were performed. In a fixed "long-term screening cohort," the authors considered the cumulative impact of repeated screening at 3-year intervals by restricting the cohort to women first cotested in 2003 through 2004 (ie, no women entering screening later were added to this group).
Detection of cervical intraepithelial neoplasia 3/adenocarcinoma in situ (CIN3/AIS) increased in the open cohort (2004-2006: 82.0/100,000 women screened; 2007-2009: 140.6/100,000 women screened; and 2010-2012: 126.0/100,000 women screened); cancer diagnoses were unchanged. In the long-term screening cohort, the detection of CIN3/AIS increased and then decreased to the original level (2004-2006: 80.5/100,000 women screened; 2007-2009: 118.6/100,000 women screened; and 2010-2012: 84.9./100,000 women screened). The number of cancer diagnoses was found to decrease. When viewed in terms of screening efficiency, the number of colposcopies performed to detect a single case of CIN3/AIS increased in the cohort with repeat screening.
Repeated cotesting at a 3-year interval eventually lowers population rates of precancer and cancer. However, a greater number of colposcopies are required to detect a single precancer. Cancer 2016;122:3682-6. © 2016 American Cancer Society.
宫颈癌筛查的目标是检测并治疗癌前病变,以预防宫颈癌导致的死亡和发病,同时尽量减少对良性人乳头瘤病毒(HPV)感染及相关轻微异常的过度治疗。在美国,目前推荐每5年进行一次HPV/细胞学联合检测作为筛查策略,但延长检测间隔存在争议。在本研究中,作者调查了另一种3年联合检测策略在北加利福尼亚州凯撒医疗集团实施十年对癌前病变和癌症发生率的影响。同时也考虑了对筛查效率的影响,筛查效率定义为检测一例癌前病变所需的联合检测/阴道镜检查次数。
定义了两个队列。“开放队列”包括在研究期间至少接受过一次筛查的所有女性;共进行了超过100万次联合检测。在一个固定的“长期筛查队列”中,作者通过将队列限制为2003年至2004年首次接受联合检测的女性(即不纳入之后开始筛查的女性),来考虑每3年重复筛查的累积影响。
在开放队列中,宫颈上皮内瘤变3级/原位腺癌(CIN3/AIS)的检出率有所增加(2004 - 2006年:每100,000名接受筛查的女性中有82.0例;2007 - 2009年:每100,000名接受筛查的女性中有140.6例;2010 - 2012年:每100,000名接受筛查的女性中有126.0例);癌症诊断数量未变。在长期筛查队列中,CIN3/AIS的检出率先增加后降至初始水平(2004 - 2006年:每100,000名接受筛查的女性中有80.5例;2007 - 2009年:每100,000名接受筛查的女性中有118.6例;2010 - 2012年:每100,000名接受筛查的女性中有84.9例)。发现癌症诊断数量有所减少。从筛查效率来看,在重复筛查的队列中,检测一例CIN3/AIS所需的阴道镜检查次数增加。
每3年重复进行联合检测最终会降低人群中癌前病变和癌症的发生率。然而,检测一例癌前病变需要更多的阴道镜检查。《癌症》2016年;122:3682 - 6。©2016美国癌症协会